Occam Places Ann Taylor as Board Member at Comanche Biopharma
Comanche is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Investors include GV, F-Prime, and Population Health Partners. The company has just appointed Ann Taylor to its Board of Directors.
Ann has an extraordinary record of achievement as a clinical development professional, with a distinguished career spanning Academia and Big Pharma. She most recently served as CMO of AstraZeneca and had previously spent a decade at Novartis leading portfolio management at NIBR, following two decades at Harvard and MassGen. She currently serves on the Boards of Terns Pharmaceuticals and Unlearn, a private company applying AI to clinical trials.
Ann has an MD from Harvard Medical School.
Related Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.